US/UK: Pfizer, AstraZeneca merger bites the dust (Competition Policy International)

Just days after UK pharmaceutical firm AstraZeneca rejected a $119 billion acquisition bid, Pfizer says it will no longer pursue the acquisition, ending the chances of a new top industry player of emerging.

Pfizer announced Monday it would no longer pursue AstraZeneca and would not consider a hostile takeover bid. Under …read more

Source: Global Competition Law Blogs